Bpifrance

MSInsight is a bioinformatics startup specializing in the development of diagnostic and treatment response prediction solutions for microsatellite instability (MSI) cancers. The company offers a platform that utilizes next-generation sequencing data to analyze MSI status, a crucial biomarker in oncology. By providing actionable insights on this biomarker, MSInsight enables healthcare professionals to make informed decisions about patient care, particularly concerning treatment options such as immunotherapy. The focus on diagnostic and prognostic biomarkers of treatment response enhances the ability to improve overall patient outcomes in the oncology market.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Founded in 2016, Vaxinano is a biotechnology company dedicated to the preclinical and pharmaceutical development of human and veterinary vaccines. It specializes in creating vaccines and drug delivery systems that selectively target difficult pathogens like parasites, viruses, or bacteria.

Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

Biodol Therapeutics develops first-in-class therapies for chronic pain by targeting the FLT3 receptor, a receptor tyrosine kinase expressed on sensory neurons that triggers and sustains neuropathic pain. The company advances extracellular inhibitors of FLT3 to block ligand binding and disrupt pain signaling, with goals to reduce allodynia, hypersensitivity and spontaneous pain while preserving normal nervous system function. By pairing FLT3 inhibition with opioid analgesia, Biodol Therapeutics aims to enhance pain relief and potentially lower opioid-related safety risks. Founded in 2015 and based in Clapiers, France, the company collaborates with academic researchers to validate FLT3 as a therapeutic target for chronic pain.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

May Health is a healthcare company focused on addressing infertility related to Polycystic Ovary Syndrome (PCOS). The company has developed an innovative, minimally invasive procedure aimed at restoring ovulation in women with PCOS. This one-time treatment is performed transvaginally under ultrasound guidance, allowing for its execution in a clinical setting without the need for general anesthesia. May Health's approach seeks to provide patients with a more natural pregnancy experience by assisting the body to ovulate as it would naturally, thereby offering a less medicalized alternative to traditional fertility treatments.

Klineo is a healthcare platform focused on enhancing access to clinical trials for oncology patients. It features an intuitive and intelligent search interface that caters to both healthcare professionals and patients. The platform allows users to efficiently locate relevant clinical trials for specific conditions such as breast, skin, and lymphoma cancers, facilitating contact with trial centers and improving the overall trial search experience. By connecting patients and doctors with appropriate clinical research opportunities, Klineo aims to streamline the process of finding critical treatment options in the oncology field.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Diamidex SAS, established in 2014 and based in Marseille, France, specializes in the development and production of rapid detection tests for legionella, a type of bacteria that can cause severe lung infections. The company offers turnkey test solutions, designed for both laboratory and field use, which provide semi-quantitative counts of microorganisms in water samples and industrial goods. Diamidex's products aim to enhance the accuracy and speed of microbial contamination detection, facilitating more efficient screening and data collection in research and testing environments.

EverImmune specializes in developing live biotherapeutic products designed to enhance the efficacy of immunotherapy for cancer patients. Its flagship product, Oncobax®, aims to restore responsiveness to immune checkpoint inhibitors by leveraging gut microbiota.

Resolve Stroke, headquartered in Paris, is a HealthTech company dedicated to revolutionizing medical imaging. It specializes in enhancing ultrasound technology to extract more detailed information, enabling advanced diagnostics, particularly in neurology. The company's innovative software engines improve ultrasound contrast, resolution, and penetration depth, allowing for the visualization of micro-vessels through the human skull in 3D. With a global focus, Resolve Stroke aims to accelerate treatments for over 1 billion people affected by brain diseases. To date, it has secured €3 million in pre-seed funding to pioneer software-based ultrasound innovation.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and Decentralized Clinical Trial solutions, focused on enhancing the efficiency and quality of data collection in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has specialized in eCOA solutions across various phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. Kayentis has adapted to the evolving clinical research landscape by offering a comprehensive suite of services aimed at supporting science-driven and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, Kayentis provides a range of adaptable tools to streamline electronic data capture, simplifying the clinical trial process for both patients and research sites.

AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Clarity is a clinical-stage company pioneering a new category of non-pharmacological treatments for neurodegenerative diseases. We develop a neuromodulation device combining immersive technology, AI and biosensors to deliver gamma sensory stimulation. Gamma waves’ sensory stimulation has been shown to significantly slow down Alzheimer's progression, reducing neurodegeneration and cognitive decline. Clarity takes a platform approach by enabling the customization of sensory stimulation protocols based on patient data, improving experience, efficacy and scalability across a wide range of indications. The company was founded by neuroscientists from UC Berkeley, and Oxford along with execs from OURA and Philips, and is supported by leading institutions such as UCSF's Neuroscape.

Jalon Therapeutics is a biotechnology company focused on developing cancer therapies by inactivating essential tumor signaling pathways through disruption of protein-protein interactions. The company aims to identify novel therapeutic targets, including through non-oncogene addiction, and to develop anticancer treatment strategies that advance patient outcomes.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.

Founded in 2019, DeepLife is a biotechnology company based in Paris, France. It specializes in developing digital twins of cells to accelerate drug discovery. The company uses advanced modeling techniques and deep learning on multi-omics data to simulate cell responses and identify new targets, biomarkers, and potential drug candidates.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in inflammation resolution, aiming to inhibit specific processes in the early stages of inflammation and the recruitment of innate immune cells. By leveraging monoclonal antibodies, Thabor Therapeutics seeks to provide effective solutions for healthcare providers to treat patients suffering from these conditions.

DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, delivering biologically active compounds to the immune system through the skin using its Viaskin platform. Its lead product candidate, Viaskin Peanut, targets peanut allergy and is advancing for use in children aged 4 to 11 and other age groups. The company is developing Viaskin Milk for immunotherapy of cow’s milk protein allergy and milk-induced eosinophilic esophagitis, Viaskin Egg in preclinical development for egg allergy, and a booster vaccine for Bordetella pertussis. Additional early-stage programs include efforts against respiratory syncytial virus, Crohn’s disease, celiac disease, and type 1 diabetes. DBV Technologies has collaborations to expand its diagnostic capabilities, including a patch-based test with Nestlé Health Science for non-IgE mediated CMPA. Founded in 2002 and headquartered in Montrouge, France, the company emphasizes skin-delivered immunotherapy as its core approach.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.

Priothera is a clinical-stage biotechnology company developing orally administered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company focuses on reducing the egress of T cell subsets from lymphatic tissue to enhance the curative potential of allogeneic hematopoietic stem cell transplantation, enabling dual inhibition of graft-versus-host disease while strengthening graft-versus-leukemia effects. Its lead program, mocravimod, aims to improve outcomes for patients undergoing HSCT. Priothera was incorporated in 2020 and is based in Dublin, Ireland, with an additional location in Saint Louis, France.

Brenus Pharma develops allogeneic cell-based immunotherapies for solid tumors. The company creates allogeneic cell vaccines to empower immune cells in vivo to recognize and attack cancer, by mimicking tumor properties and increasing visibility to the immune system. Its platform aims to educate the immune system to anticipate relapse mechanisms by stimulating selected tumor cell lines, enabling clinicians to induce responses during chemotherapy or radiotherapy. The approach seeks to prevent cancer resistance to treatment and improve durability of responses across solid tumors.

Founded in 2017 and based in Toulouse, France, Cell-Easy operates as a stem cell Contract Development and Manufacturing Organization (CDMO). It specializes in providing ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical development projects.

Cureety is a healthcare technology company offering a telemedicine and telemonitoring platform for remote patient follow-up, with a focus on oncology. The platform collects patient-reported outcomes, applies clinical algorithms tailored to different treatments, and provides personalized support services to patients. By enabling remote monitoring, Cureety helps healthcare professionals prioritize care for vulnerable patients and improve the quality of cancer care.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

Pherecydes Pharma specializes in the research and development of lytic bacteriophages for therapeutic applications, focusing on antibiotic resistance. Established in 2006, the company is based in Romainville, France.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

Lysogene S.A. is a biotechnology company based in Neuilly-sur-Seine, France, focused on the research and clinical development of gene therapy for neurodegenerative disorders. Founded in 2009, the company is advancing several clinical programs, including LYS-SAF302, currently in Phase II/III trials for the treatment of mucopolysaccharidosis type IIIA, and LYS-GM101, which is in Phase I/II trials for GM1 gangliosidosis. Lysogene is also engaged in a collaborative research effort with the Weizmann Institute of Science to develop a novel AAV gene therapy approach targeting neuronopathic Gaucher disease, Parkinson's disease, and other conditions. The company aims to enhance the health outcomes of patients suffering from life-threatening, incurable disorders by utilizing AAV vectors that effectively deliver genetic material to the central nervous system.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

PEP-Therapy is a biotechnology company specializing in the development of innovative peptide-based therapies aimed at treating severe diseases, with a primary emphasis on cancer. The company focuses on creating Cell Penetrating and Interfering Peptides, which are designed for intracellular delivery of targeted treatments. These peptides effectively penetrate cell membranes to block crucial intracellular protein-protein interactions, thereby inhibiting important pathogenic mechanisms associated with various diseases. By harnessing the potential of these active compounds, PEP-Therapy aims to advance therapeutic options in oncology and beyond.

Inotrem is a biotechnology company specializing in immunotherapy for acute and chronic inflammatory syndromes. It has developed a proprietary technology platform targeting the TREM-1 pathway to control unbalanced inflammatory responses, leading to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in septic shock and myocardial infarction.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

OncoDiag is a biotechnology company based in Normandy, France, specializing in the development of non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, Urotest, is a urine test designed for the diagnosis and monitoring of bladder cancer. Additionally, the company is advancing its pipeline with Colodiag, which focuses on the early detection of colorectal cancer. OncoDiag's portfolio also includes a tissue-based test for predicting non-evolutive localized prostate cancer. By offering these innovative diagnostic solutions, OncoDiag aims to enhance the capabilities of healthcare professionals in cancer diagnosis and management.

Argobio is a startup studio dedicated to cultivating innovative biotechnology solutions. It sources early-stage projects from leading European academic institutions focusing on rare diseases, neurological disorders, oncology, immunology, and platform technologies for therapeutic products.

NovAliX specializes in supporting pharmaceutical industry outsourcing needs through advanced technologies. It offers integrated services for small molecule drug discovery using proprietary Surface Plasmon Resonance (SPR) technology, X-ray protein crystallography, supramolecular mass spectrometry, and chemistry. Additionally, NovAliX provides detailed characterization of biologics, API analysis, and polymorphism studies to aid pharmaceutical development and manufacturing.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and Decentralized Clinical Trial solutions, focused on enhancing the efficiency and quality of data collection in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has specialized in eCOA solutions across various phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. Kayentis has adapted to the evolving clinical research landscape by offering a comprehensive suite of services aimed at supporting science-driven and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, Kayentis provides a range of adaptable tools to streamline electronic data capture, simplifying the clinical trial process for both patients and research sites.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative implantable medical devices aimed at restoring vision for individuals blinded by the degeneration of photoreceptor cells in the retina. The company’s flagship product, the PRIMA System, is a bionic vision system designed to improve visual acuity and enhance the independence of patients. Pixium Vision also works on the Intelligent Retinal Implantable System (IRIS1), which is currently undergoing clinical trials, and is developing two subsequent generations, IRIS2 and IRIS3, each designed to provide improved visual capabilities through advanced technologies. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with prestigious institutions such as Stanford University and Moorfields Eye Hospital to further its research and development efforts in retinal implant systems.

Founded in 2017, Synapse Medicine is a French company that designs and develops an online platform providing reliable, up-to-date drug information for doctors. It offers a global knowledge base and SaaS platform to facilitate medication prescription, dispensing, and management across the patient journey.

ABC Transfer is a biopharmaceutical company specializing in the development of Rapid Transfer Systems (RTS) solutions. It manufactures secure transfer systems specifically designed for sterile drug manufacturing and bioprocessing. The company's innovative systems utilize patented components such as alpha doors, beta containers, and single-use bags. These systems enhance sterility assurance, promote operator safety, and improve overall efficiency in pharmaceutical manufacturing processes.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Cureety is a healthcare technology company offering a telemedicine and telemonitoring platform for remote patient follow-up, with a focus on oncology. The platform collects patient-reported outcomes, applies clinical algorithms tailored to different treatments, and provides personalized support services to patients. By enabling remote monitoring, Cureety helps healthcare professionals prioritize care for vulnerable patients and improve the quality of cancer care.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Inotrem is a biotechnology company specializing in immunotherapy for acute and chronic inflammatory syndromes. It has developed a proprietary technology platform targeting the TREM-1 pathway to control unbalanced inflammatory responses, leading to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in septic shock and myocardial infarction.

Urania Therapeutics is a biopharmaceutical company focused on the identification and development of readthrough compounds aimed at treating genetic diseases and certain cancers. The company utilizes a proprietary structure-based drug design platform to create novel therapeutic treatments that address conditions caused by mutations, specifically those involving premature stop codons during protein synthesis. By enabling the production of full-length, functional proteins, Urania Therapeutics targets a range of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its innovative approach, the company seeks to restore normal protein production, offering potential new solutions for patients with these challenging genetic conditions.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

NH TherAguix SAS is a clinical-stage pharmaceutical company based in Villeurbanne, France, focused on the development of nanomedicines for cancer treatment. The company specializes in creating innovative therapeutics that enhance radiotherapy for solid tumors. Its lead product, AGuIX, is a theranostic nanoparticle designed to improve the localization of tumors and optimize radiation therapy outcomes. By facilitating intravenous administration, AGuIX enables healthcare professionals to determine the best timing for irradiation, targets tumor tissues more effectively, and minimizes adverse effects on healthy tissues by reducing radiation doses. Founded in 2015, NH TherAguix is dedicated to advancing cancer treatment through its pioneering approach to combining imaging and radiotherapy.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

C4Diagnostics is a developer of in vitro diagnostic (IVD) kits that leverages proprietary technology to enhance the speed and sensitivity of diagnostic testing. The company focuses on creating medical devices and equipment that streamline the screening process for urinary tract infections, allowing for the reliable detection, counting, and concentration of relevant microorganisms in clinical microbiology. By enabling hospitals and laboratories to conduct culture-based IVD tests and specific fluorescence assessments, C4Diagnostics contributes to more efficient and effective diagnostic practices in healthcare settings.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.

Nosopharm SAS is a biotechnology company focused on the research and development of innovative antibacterial molecules to combat the growing threat of multidrug-resistant infections, particularly in hospital settings. Established in 2009 and headquartered in Nimes, France, Nosopharm specializes in Odilorhabdins, a novel class of antibiotics designed to target resistant gram-negative pathogens such as Escherichia coli and Pseudomonas aeruginosa. The company's lead product, NOSO-95179, is a first-generation Odilorhabdin aimed at treating Carbapenem-resistant Enterobacteriaceae infections, while NOSO-95400 represents a second-generation option for addressing a broader range of multidrug-resistant bacteria. Nosopharm employs an innovative drug discovery platform that leverages the medicinal properties of microbial biodiversity, particularly focusing on metabolites from the bacterial genera Xenorhabdus and Photorhabdus. Through its dedicated efforts, Nosopharm seeks to address the critical medical need for effective treatments against hospital-acquired infections.

TxCell develops cellular immunotherapies using regulatory T cells for treating severe chronic inflammatory diseases with high medical need. Its proprietary platform focuses on Type 1 regulatory T lymphocytes (Tr1 cells), with clinical trials underway for refractory Crohn's disease and planned for rheumatoid arthritis.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.